SEMAGLUTIDE 2.4 MG IN PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: BASELINE CHARACTERISTICS AND DESIGN OF THE PHASE 3 ESSENCE TRIAL

Descargar Publicación
Characterizing GLP-1 Receptor Agonist Use in Preadolescent and Adolescent Populations Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease